Ani Pharmaceuticals (ANIP) Capital Expenditures (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Capital Expenditures data on file, last reported at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 494.32% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (up 1754.71% YoY), and the FY2025 full-year result was $1.0 million, up 98.49% from the prior year.
• Capital Expenditures advanced to $6.1 million in Q1 2026, from -$11.5 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $12.2 million in Q3 2024 to a low of -$13.3 million in Q4 2024.
• A 5-year average of $496058.8 and a median of $526000.0 in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures sank 16535.8% in 2024 and surged 1280.3% in 2025, its largest moves.
• Tracing ANIP's Capital Expenditures over 5 years: stood at $248000.0 in 2022, then plunged by 67.34% to $81000.0 in 2023, then slumped by 16535.8% to -$13.3 million in 2024, then rose by 13.31% to -$11.5 million in 2025, then jumped by 152.63% to $6.1 million in 2026.
• Business Quant data shows ANIP's Capital Expenditures at $6.1 million in Q1 2026, -$11.5 million in Q4 2025, and $6.1 million in Q3 2025.